Here's the question worth asking out loud: if mRNA just tells cells to make a protein, why did it take decades to turn into medicine? Two problems. First, the body treats foreign RNA as a threat and attacks it. Second, RNA falls apart almost instantly and can't get into cells on its own. Solving both is what made the modality real.
The first fix is chemical. You modify the mRNA's building blocks so the body doesn't raise an alarm and so it survives long enough to be read. Moderna's foundational grants US10501513B2 and US10501512B2 (both "Modified polynucleotides," 2019) are squarely about this — engineered mRNA designed to be translated into protein inside the body without triggering the defenses that destroy ordinary RNA.
The second fix is packaging, and that's where lipid nanoparticles come in. Think of it like shipping something fragile: you don't mail a raw egg, you put it in a protective carton. The lipid nanoparticle is that carton — a microscopic sphere of fats that encases the mRNA, shields it in the bloodstream, and helps it slip inside cells. The fats aren't generic; the key ingredient is an "ionizable" lipid tuned to release its cargo at the right moment.
The patent record shows how active this delivery layer still is. A June 2026 grant, US12648908B2 ("Cationic lipid, liposome... and nucleic-acid pharmaceutical composition"), and a published application, US20260159480A1 ("Ionizable lipid and use thereof"), are both about the carrier chemistry, not the genetic payload. In plain terms, the industry largely settled how to write the instructions; the live competition is over the envelope they travel in.
Why split the modality into payload and packaging? Because they're separately ownable, separately improvable, and separately valuable. A better lipid can make the same mRNA safer, more potent, or able to reach a new tissue. That's why so much recent IP clusters on the nanoparticle — incremental delivery improvements are where a lot of the next decade of mRNA value will be captured.
So when you hear "mRNA vaccine," hold both pieces in mind. There's the message — modified genetic instructions, the part Moderna's early patents locked down — and there's the messenger, the lipid nanoparticle that gets it where it needs to go. The newest grants tell you the field's attention has moved to the delivery bubble.